|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
WHO007045298 |
| 003 |
DE-627 |
| 005 |
20230605131224.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
210507s2023 xx |||||o 00| ||eng c |
| 035 |
|
|
|a (DE-627)WHO007045298
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)RBR-4n5mkh
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 245 |
1 |
0 |
|a Oral Estrogen use in treatment of women with Acromegaly
|b Evaluation of the efficacy and security of oral Estrogen use in the treatment of female patients with Acromegaly
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 04-03-2020, Last updated: 2023-06-05
|
| 650 |
|
4 |
|a Medical Condition: Study conducted: women with disease: Acromegaly.Target population: Female (childbearing age), volunteers of the intervention female with uncontrolled Acromegaly. Medicine: formulation oral of ethynil estradiol 0.03mg + levonorgestrel 0.15mg. Acromegaly, Growth Hormone-Secreting Pituitary Adenoma, pituitary disease, pituitary neoplasms.;E22.0;C04.557.470.035.415;C10.228.140.617.738;C04.588.322.609
|
| 650 |
|
4 |
|a Study Type: Interventional
|
| 650 |
|
4 |
|a Recruitment Status: Recruiting
|
| 650 |
|
4 |
|a 610
|
| 773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2023) vom: 29. Mai
|
| 773 |
1 |
8 |
|g year:2023
|g day:29
|g month:05
|
| 856 |
4 |
0 |
|u http://ensaiosclinicos.gov.br/rg/RBR-4n5mkh
|z kostenfrei
|3 Volltext
|
| 912 |
|
|
|a GBV_CTG
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2023
|b 29
|c 05
|
Klinische Studie